SEC Form 4 · accession 0001437749-19-002338
NAVIDEA BIOPHARMACEUTICALS, INC. · NAVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sarah Kathryn Rouan
Director
Period of report
Feb 7, 2019
Accepted (ET)
Feb 12, 2019 · 4:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000810509
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 7, 2019 | A | 50,000 | $0.001 | A | 100,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option | $0.25 | Feb 7, 2019 | A | 50,000 | A | Feb 7, 2020 | Feb 7, 2029 | Common Stock | 50,000 | 100,000 | D |
Explanation of responses
- F1Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant.